PBI3 ANÁLISIS DEL COSTO POR RESPONDEDOR DE SECUKINUMAB VS INFLIXIMAB Y ETANERCEPT PARA EL TRATAMIENTO DE LA ARTRITIS PSORIÁSICA DESDE UNA PERSPECTIVA ECUATORIANA

Abstract

Authors

G.F. Afanador Echeverri

Full Text Cite This Article
Back to Volume 19, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×